Company intelligence / Profile preview

Lumativa

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Lumativa is an emerging biotechnology company focused on developing next-generation cancer therapies that target mitochondrial metabolism. The company's lead programs utilize a proprietary platform to identify and inhibit specific mitochondrial pathways that fuel tumor growth and resistance to standard treatments. By disrupting the energy production of cancer cells, Lumativa aims to provide more effective options for patients with difficult-to-treat solid tumors. The company is currently advancing its pipeline through pre-clinical validation with the goal of entering clinical trials in the near future.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Lumativa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lumativa.

Explore the full profile